

EQUITY OVERVIEW

Ticker (Exchange)	GANX (NASDAQ-GM)
Stock Price (USD)	\$4.56
Market Cap	~\$74M
Cash ¹	~\$22.1M
Outstanding Shares ²	16.2M
52-Week Range	\$2.00 - \$6.19
Avg. Daily Volume	~168,000
Analyst Coverage	BTIG – Thomas Schrader Oppenheimer & Co. – Hartaj Singh H.C. Wainwright - Raghuram Selvaraju Chardan – Keay Nakae Maxim – Jason McCarthy

All figures as of 3/12/2024 unless otherwise noted (Source: NASDAQ)
¹ Cash, cash equivalents and marketable securities as of Nov. 2023
² Form 10-Q filed on 11/14/2023 + shares issued in Nov. 2023 financing

INVESTMENT HIGHLIGHTS

Clinical-stage lead program GT-02287 for Parkinson's disease with multiple value inflection points in upcoming 12 months

Clinically validated AI-drug discovery platform now accesses chemical space in excess of 50 billion compounds

Awarded \$2.8M grant to advance lead program in Parkinson's disease

UPCOMING MILESTONES

1H 2024

- Completion of Phase 1 clinical trial in healthy volunteers – safety of GT-02287 in humans
- Protocol amendment for first-in-patient (FIP) cohort in Phase 1 clinical trial

2H 2024

- Start of patient cohort in Phase 1 clinical trial
- Pre-IND meeting with the FDA

1H 2025

- Biomarker-based clinical proof of concept from patient cohort in Phase 1 clinical trial
- US IND filing
- Start of Phase 2 clinical trial

CONTACT

Gain Therapeutics, Inc.
 4800 Montgomery Lane, Ste. 220
 Bethesda, MD 20814
 P: +1 301-500-1556
www.gaintherapeutics.com

Investor Contact

CORE IR
 (516) 222-2560
ir@gaintherapeutics.com

Leading the Discovery of New Therapies with Allosteric Modulators

Gain Therapeutics, Inc. is a clinical-stage biotechnology company accelerating drug discovery and unlocking novel disease-modifying treatments. Deploying our highly advanced platform, we are identifying and targeting never-before-seen allosteric binding sites on disease-implicated proteins and proprietary small molecules with **first-in-class** or **best-in-class** profiles.

Lead Program with Disease-Modifying Potential in GBA1-Parkinson's disease

Borne of our proprietary platform, our lead program GT-02287 is targeting GBA1-Parkinson's Disease (GBA1-PD). GT-02287 is an oral, brain penetrant small molecule that restores the function of the lysosomal enzyme glucocerebrosidase (GCase) which becomes misfolded and impaired due to mutations of the GBA1 gene, the largest genetic risk factor associated with PD. In preclinical models of PD, GT-02287 restored GCase enzymatic function, reduced aggregated α -synuclein, neuroinflammation and neuronal death, increased dopamine levels, completely restored motor function and reduced neurofilament light chain (NfL), an emerging biomarker for neurodegeneration, to normal levels. Based on this best-in-class preclinical data package, GT-02287 has the potential to **stop progression of Parkinson's** and other neurodegenerative diseases.

Our Magellan™ Drug Discovery Platform

Leveraging AI-supported structural biology, proprietary algorithms and supercomputer-powered physics-based models, our Magellan discovery platform can identify novel allosteric binding sites on proteins, pinpointing pockets that cannot be found or drugged with current technologies. Magellan allows us to create new medicines that activate, inhibit, stabilize, destabilize and degrade proteins based on disease biology.

Our Strategy for Value Creation

Pipeline Progression – We are planning to progress our lead program GT-02287 to a biomarker-based clinical proof of concept in Parkinson's disease in the next 12 months.

Deal Making – We expect to generate license revenues through partnering of our pipeline programs and applying Magellan™ in research collaborations with industry partners.

Grant Funding – We anticipate building on our track record of securing non-dilutive grant funding to advance our innovative science and product pipeline.

INDICATION	TARGET	DISCOVERY	RESEARCH	PRECLINICAL	PHASE 1	PHASE 2
Parkinson's Disease	GCase	[Progress bar from Discovery to Phase 1]				
Dementia with Lewy Bodies Alzheimer's Disease	GCase	[Progress bar from Discovery to Research]				
Gaucher Disease	GCase	[Progress bar from Discovery to Preclinical]				
GM1 Gangliosidosis	GLB1	[Progress bar from Discovery to Research]				
Krabbe Disease	GALC	[Progress bar from Discovery to Research]				
Alpha1-Antitrypsin Deficiency	AAT	[Progress bar from Discovery to Research]				
Solid Tumors	TO BE DISCLOSED	[Progress bar from Discovery to Research]				
Solid Tumors	TO BE DISCLOSED	[Progress bar from Discovery to Research]				

● Neurodegeneration ● Lysosomal Storage Disorders ● Metabolic Disorders ● Oncology